Overview

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia

Status:
Completed

Trial end date:
2015-12-31

Target enrollment:

Participant gender:

Summary

To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.

Phase:

Phase 3

Details

Lead Sponsor:

Celator Pharmaceuticals
Jazz Pharmaceuticals

Collaborator:

The Leukemia and Lymphoma Society

Treatments:

Cytarabine
Daunorubicin